MindMed prices $225M public offering of 18.375M shares at $12.25/sh; upsize to $258.9M after full over-allotment

Definium Therapeutics, Inc.

Issued 18,375,000 common shares at $12.25 per share; underwriters exercised option for additional 2,756,250 shares.
Gross proceeds of $258.9M; net proceeds of $242.8M after underwriting discounts and estimated expenses.
Offering closed October 31, 2025; Jefferies, Leerink Partners, Evercore ISI as joint bookrunners.
Net proceeds to fund R&D of product candidates, working capital, and potential complementary acquisitions.
Directors and executive officers subject to 90-day lock-up on share sales without consent.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.